On the Super Trades watchlist.

 

In a new report, analysts at Leerink previewed the upcoming American Society of Clinical Oncology (ASCO) Conference. Analysts broke down what investors need to watch for from the companies presenting at the event.

Affimed NV (NASDAQ: AFMD) (Outperform)

Analysts see the preclinical presentation on the combination of AFM13 and CD137 co-stimulation and PD-1 blocking as the “most interesting” topic from the company.

Array BioPharma Inc (NASDAQ: ARRY) (Outperform)

Analysts are watching for updates on multiple binimetinib (MEK162) combinations.

Cerulean Pharma Inc (NASDAQ: CERU) (Outperform)

Analysts are looking for final data from the Phase 1b/2a trial of CRLX101 with avastin for treatment of renal cell carcinoma.

Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) (Outperform)

Analysts would view early disclosure of clinical data from DCR-MYC as a positive.

Exelixis Inc (NASDAQ: EXEL) (Market Perform)

Analysts will be watching for several potential updates on cabozantinib and cobimetinib.

ImmunoGen Inc (NASDAQ: IMGN) (Market Perform)

Analysts believe investors will mostly be looking for results from the Roche MARIANNE study, but feel that data on IMGN853 could also be coming.

Incyte Corp (NASDAQ: INCY) (Outperform)

Analysts are most eager to see data from two Phase I trials of INCB040093 and INCB039110 in B cell malignancies and Hodgkin Lymphoma.

Karyopharm Therapeutics Inc (NASDAQ: KPTI) (Outperform)

Analysts believe that potential Phase 2 data from solid tumor studies could serve as a near-term catalyst for the stock.

MacroGenetics Inc (NASDAQ: MGNX) (Outperform)

Analysts will be watching Phase I data on margetuximab monotherapy in HER2-positive solid tumors.

Mirati Therapeutics Inc (NASDAQ: MRTX) (Outperform)

Analysts want to see at least a 50 percent response rate in the first 10-15 patients of the Phase I study of MGCD265 in patients with advanced solid tumors.

Xencor Inc (NASDAQ: XNCR) (Outperform)

 

Analysts see XmAb7195 and XmAb5871 as the two main drivers for the company, but believe that MOR208 could provide a nice pipeline complement to the two proprietary antibodies.